Orchestra BioMed Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Orchestra BioMed Hldgs (OBIO).

Price Target Range — 11 Quarters

Analyst Consensus — 8 Analysts

8Buy

Consensus RatingBuy# Analysts8Avg. Consensus PT$13Upside to Avg. PT+114.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	B. Riley Securities	Madison El-Saadi	PT Raise	Buy	$10→$11
Sep 10, 2026	BTIG	Marie Thibault	Upgrade	Neutral→Buy	$10
Aug 11, 2026	Piper Sandler	Matt O'Brien	PT Raise	Overweight	$9→$10
May 19, 2026	B. Riley Securities	Kyle Bauser	PT Cut	Buy	$12→$10
May 14, 2026	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$10
May 13, 2026	Barclays	Matt Miksic	PT Raise	Overweight	$12→$13
Mar 12, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$20
Jan 9, 2026	Barclays	Matt Miksic	PT Raise	Overweight	$11→$12
Dec 10, 2025	TD Cowen	Joshua Jennings	Initiate	Buy	$15
Nov 13, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$20
Nov 12, 2025	Barclays	Matt Miksic	PT Cut	Overweight	$12→$11
Sep 4, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$12→$10
Aug 20, 2025	BTIG	Marie Thibault	Downgrade	Buy→Neutral	—
Aug 13, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$20
Aug 7, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$20
May 13, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$20
May 5, 2025	Barclays	Matt Miksic	PT Cut	Overweight	$16→$12
Apr 22, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$20
Apr 4, 2025	HC Wainwright & Co.	Yi Chen	PT Cut	Buy	$14→$12
Apr 1, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$20

More with Benzinga EdgeGet Access

Analyst Ratings News

This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday

Analysts upgraded Copart, Orchestra BioMed, Illumina, Martin Marietta Materials and Waters, raising their price targets.

Avi Kapoor

This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Analysts upgraded SFNC, OBIO, and more.

Avi Kapoor

PRO
BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target

BTIG analyst Marie Thibault upgrades Orchestra BioMed Hldgs (NASDAQ:OBIO) from Neutral to Buy and announces $10 price target.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10

Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10

B. Riley Securities analyst Kyle Bauser maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and lowers the price target from $12 to $10.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target

HC Wainwright & Co. analyst Yi Chen reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $10 price target.

Benzinga Newsdesk

Orchestra BioMed Holdings Inc

Orchestra BioMed Hldgs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday

This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PRO
BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target

PRO
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10

PRO
B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10

PRO
HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target

People Also Watch

People Also Watch

Orchestra BioMed Holdings Inc

Orchestra BioMed Hldgs Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Copart Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday

This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PROBTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target

PROPiper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10

PROB. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10

PROHC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target

People Also Watch

People Also Watch

PRO
BTIG Upgrades Orchestra BioMed Hldgs to Buy, Announces $10 Price Target

PRO
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10

PRO
B. Riley Securities Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10

PRO
HC Wainwright & Co. Reiterates Buy on Orchestra BioMed Hldgs, Maintains $10 Price Target